ResMed: A Mixed Bag for Investors Amid Rising Competition

A Motley Fool Scoreboard episode featured ResMed (RMD) in a video published on June 10, 2025, using stock prices from May 7, 2025; however, Motley Fool analysts did not include ResMed in their current list of top 10 stocks, which they believe could produce significant returns. The Stock Advisor's average return is 999% versus 173% for the S&P 500. The Motley Fool recommends ResMed.

Analysis

A Motley Fool Scoreboard episode, published June 10, 2025, and using stock prices from May 7, 2025, featured ResMed (RMD) but notably excluded it from The Motley Fool Stock Advisor's latest "10 best stocks for investors to buy now" list. This omission is significant given the Stock Advisor service's historical outperformance, with a claimed 999% average return compared to the S&P 500's 173%, and its record of selecting stocks like Netflix and Nvidia that delivered substantial returns. Despite this exclusion, The Motley Fool as an entity reportedly has positions in and recommends ResMed, creating a nuanced signal for investors. The per-ticker sentiment for RMD registered at -0.3, diverging from the article's overall "strongly positive" general sentiment score of 0.7, which appears to reflect the promotional nature of the content regarding the Stock Advisor service itself rather than a bullish outlook on ResMed. Therefore, while ResMed receives a general endorsement from The Motley Fool, its absence from the premium "top 10" list suggests it was not identified by their analyst team as one of the most compelling opportunities for outsized gains at the time of publication.

Key Decisions for Investors

• Investors should interpret ResMed's exclusion from The Motley Fool's "10 best stocks" list, coupled with a -0.3 per-ticker sentiment, as an indication that it may not currently be viewed by this specific analyst team as a top candidate for rapid, high-magnitude growth, despite a broader organizational recommendation.
• Evaluate ResMed's fit within a portfolio, particularly if seeking "monster returns" similar to those historically generated by Stock Advisor's top picks, as RMD did not make this curated list.
• Conduct further due diligence on ResMed's current fundamentals and growth prospects to understand why it was not selected for the "top 10" list, before committing new capital or adjusting existing positions.